ライフサイエンスコーパス: coronary disease

1 invasive or conservative strategy for stable coronary disease.

2 ertreatment of patients with high-complexity coronary disease.

3 and assessment of patients with symptomatic coronary disease.

4 tensive validation as a prognostic marker in coronary disease.

5 an CTA or PET in the evaluation of suspected coronary disease.

6 among individual circulating fatty acids and coronary disease.

7 eading to altered vascular effects of HDL in coronary disease.

8 tory diseases, including atherosclerosis and coronary disease.

9 ar events in patients with clinically stable coronary disease.

10 ardiovascular events in patients with stable coronary disease.

11 ve clinical outcomes in patients with stable coronary disease.

12 rategy in patients with diabetes with severe coronary disease.

13 stem who underwent CABG or PCI for new onset coronary disease.

14 rative ischemia), and none had flow-limiting coronary disease.

15 g the highest-risk patients with more active coronary disease.

16 (n=9) secondary to KD as the cause of their coronary disease.

17 ardial infarction and those with more stable coronary disease.

18 s on development of clinical atherosclerotic coronary disease.

19 declines in older individuals and those with coronary disease.

20 eloperoxidase (MPO) has been linked to acute coronary disease.

21 atomic and functional investigation of early coronary disease.

22 and function, independent of hypertension or coronary disease.

23 scular death in patients with stable chronic coronary disease.

24 rt failure, myocardial infarction, and fatal coronary disease.

25 o more than 13% of the total heritability of coronary disease.

26 management of coexisting severe carotid and coronary disease.

27 oronary intervention in patients with stable coronary disease.

28 ns known to affect survival in patients with coronary disease.

29 e left ventricular dysfunction and extensive coronary disease.

30 ndary prevention among patients with chronic coronary disease.

31 hy individuals and patients with established coronary disease.

32 ) are alternative treatments for multivessel coronary disease.

33 ients undergoing angiography had obstructive coronary disease.

34 nts with type 2 diabetes mellitus and stable coronary disease.

35 133 (76%) of 175 of patients with no to mild coronary disease.

36 diography and catheterization excluded acute coronary disease.

37 recruited on the basis of family history of coronary disease.

38 llele of the same SNP with increased risk of coronary disease.

39 onstrated the ability to slow progression of coronary disease.

40 ype 1 diabetes who have an increased rate of coronary disease.

41 The Framingham equations predict incident coronary disease.

42 iovascular events among patients with stable coronary disease.

43 ion regardless of the severity of underlying coronary disease.

44 propriate management of patients with stable coronary disease.

45 EF) influence the prognosis of patients with coronary disease.

46 re less likely to have a parental history of coronary disease.

47 ase and more likely to suffer mortality from coronary disease.

48 1-codon25 high-production is associated with coronary disease.

49 e the risk of stroke in patients with stable coronary disease.

50 table, higher-risk clinical presentations of coronary disease.

51 80.6, P<0.001) and had lower rates of prior coronary disease.

52 ine if this is influenced by any concomitant coronary disease.

53 diac Surgery) score quantifies the extent of coronary disease.

54 ardiovascular events in patients with stable coronary disease.

55 isease (CVD) in populations with established coronary disease.

56 meric scaffolds for treatment of obstructive coronary disease.

57 ng cardiovascular risk scales and predicting coronary disease.

58 to CABG in selected patients with left main coronary disease.

59 tcomes with invasive or conservative care in coronary disease.

60 lation, hypertension, diabetes mellitus, and coronary disease.

61 stable patients with symptoms suspicious for coronary disease.

62 ifying inducible ischemia due to significant coronary disease.

63 riate or uncertain indications had important coronary disease.

64 sialyltransferase and sialic acid levels and coronary disease.

65 sured in 216 stenoses from 186 patients with coronary disease.

66 0.0284] and 0.0109 [0.0059-0.0159]) than for coronary disease (0.0048 [0.0029-0.0067] and 0.0036 [0.0

67 Of 18,924 patients, 17,370 had monovascular (coronary) disease, 1,405 had polyvascular disease in 2 b

68 l coronaries had higher rates of obstructive coronary disease (59.2% vs. 51.3% vs. 52.6% vs. 44.3%; p

69 The clinical presentations were stable coronary disease (69%) and acute coronary syndromes (31%

70 P<0.001), and a higher rate of detection of coronary disease (9.0% vs. 3.5%; difference, 5.6 percent

71 consider 2 broad categories of patients with coronary disease: acute and stable.

72 Among patients with stable coronary disease, advanced chronic kidney disease, and m

73 The extent of coronary disease affects clinical outcomes and may predi

74 We pooled individuals without pre-existing coronary disease age 45 to 74 years from the ARIC (Ather

75 9.8 years) with ejection fraction </=35% and coronary disease amenable to CABG were randomized to CAB

76 e was associated with more comorbidities and coronary disease and a higher risk of recurrent MI, but

77 persistent chest pain include microvascular coronary disease and abnormal cardiac nociception.

78 ls incorporated traditional risk factors for coronary disease and CAC scores.

79 ve agents for the diagnoses of microvascular coronary disease and can be a useful tool to differentia

80 tically for detecting increasing severity of coronary disease and clinical events.

81 ls incorporated traditional risk factors for coronary disease and coronary artery calcification (CAC)

82 Coronary disease and diabetes mellitus had been diagnose

83 th and total mortality risk in patients with coronary disease and left ventricular dysfunction.

84 Among patients with stable coronary disease and moderate or severe ischemia, we did

85 Among patients with stable coronary disease and moderate or severe ischemia, whethe

86 that AA are less likely to have obstructive coronary disease and more likely to suffer mortality fro

87 ified variants were strongly associated with coronary disease and myocardial infarction.

88 with single-vessel left anterior descending coronary disease and normal ventricular function (n=13)

89 trial, in which patients with chronic stable coronary disease and preserved systolic function were ra

90 From 12 patients with coronary disease and recurrent ventricular tachycardia u

91 We projected coronary disease and stroke deaths to 2030, first on the

92 addressing the 'inflammation hypothesis' in coronary disease and stroke.

93 lar morbidity and mortality in patients with coronary disease and type 2 diabetes mellitus.

94 August 2003-March 2006) in 543 patients with coronary disease and type 2 diabetes.

95 old (mean age, 69.2+/-10.7 years), 61.9% had coronary disease, and 17.2% had class 3 obesity.

96 diabetes mellitus, 62.7% hypertension, 7.1% coronary disease, and 2.8% with known HF.

97 re, surgery for vascular disease, inoperable coronary disease, and amputation for ischemic gangrene.

98 , abnormal ventricular function, severity of coronary disease, and diabetes.

99 for age, sex, body mass index, hypertension, coronary disease, and echocardiographic parameters (HR:

100 ssion independent of age, sex, hypertension, coronary disease, and ejection fraction.

101 of incident myocardial infarction and fatal coronary disease, and evaluated discriminative and calib

102 associated with cardiovascular risk factors, coronary disease, and events.

103 adjusted for age, sex, atrial fibrillation, coronary disease, and LVAD type as time-dependent Cox pr

104 her rate of all cardiovascular risk factors, coronary disease, and myocardial infarction.

105 women, younger patients, individuals without coronary disease, and those treated with evidence-based

106 uses, cardiovascular diseases, hypertension, coronary diseases, and stroke, respectively.

107 If advances in coronary disease are to occur, it is important to recogn

108 graphy can definitively establish or exclude coronary disease as the cause of chest pain.

109 SCT alone immediately excluded or identified coronary disease as the source of chest pain in 75% of p

110 e normal coronary arteries or nonsignificant coronary disease at coronary angiography (CA).

111 scular ultrasonography in 1039 patients with coronary disease, at baseline and after 104 weeks of tre

112 pairment (ejection fraction <30%) and severe coronary disease (BCIS-1 jeopardy score >/=8; maximum po

113 V event reduction among 15,056 patients with coronary disease but without diabetes at baseline in the

114 dard of treatment for 3-vessel and left main coronary disease, but is associated with an increased ri

115 Dyslipidemia is a known risk factor for coronary disease, but its role in heart failure (HF) dev

116 gative predictive value for the detection of coronary disease, but its usefulness in determining whet

117 (58% versus 37%; P<0.0001), less obstructive coronary disease by CCTA (5% versus 17%; P=0.0001), but

118 Young women presenting with AMI may develop coronary disease by different mechanisms and often have

119 otic cores, the substrate for acute unstable coronary disease by recruiting and activating leukocytes

120 GPIIIa C1565T), involving a total of 66 155 coronary disease cases and 91 307 controls.

121 month post-MI in a New Zealand cohort (CDCS [Coronary Disease Cohort Study]) including 181 patients p

122 Some coronary disease common variants show allelic heterogene

123 A heart-team approach should evaluate coronary disease complexity, patient comorbidities, pati

124 one for acute coronary syndrome and anatomic coronary disease confirmed, the benefits and risks of in

125 For patients with acute coronary disease, coronary physiology may potentially re

126 Thus, risk of sudden death in patients with coronary disease depends on multiple variables in additi

127 inflammation who are at a high risk of acute coronary disease despite a suppressive antiretroviral th

128 e more likely to have comorbidities, such as coronary disease, diabetes mellitus, and renal insuffici

129 is neutral or beneficial for weight control, coronary disease, diabetes, hypertension, and most cance

130 beverage intake with risk of mortality from coronary diseases, diabetes, or cancer, but few studies

131 gment elevation MI found to have significant coronary disease during catheterization and who survived

132 rding to clinical factors, such as extent of coronary disease, ejection fraction, or previous procedu

133 on with unprotected left main or multivessel coronary disease, even after adjustment for known risk f

134 rdiac disease and with new heart failure and coronary disease events, but not with carotid intima-med

135 atients with myocardial damage on DE-CMR had coronary disease excluded by x-ray angiography.

136 non-ST-segment elevation MI with significant coronary disease face high long-term risks for mortality

137 The rate of obstructive coronary disease found at elective coronary angiography

138 Patients with coronary disease from 25 US cardiology outpatient practi

139 try (ACC-NCDR) records with 2- and 3- vessel coronary disease from 54 sites in 2004 to 2007.

140 g had an acceptable value for discriminating coronary disease from normal condition with optimal cuto

141 During global ischemia, hearts with coronary disease had shorter time to enter into rigor an

142 One third of patients with significant coronary disease have chronic total coronary occlusion (

143 thrombosis, but studies of such variants in coronary disease have reported apparently conflicting re

144 of revascularization in patients with stable coronary disease have routinely excluded those with adva

145 followed for 13.6 +/- 3.2 years for incident coronary disease, heart failure, and CV and all-cause mo

146 ion of selected patients suspected of having coronary disease; however, in addition to coronary asses

147 exposures were stroke, atrial fibrillation, coronary disease, hyperlipidemia, hypertension, sleep ap

148 e presence of significant moderate-to-severe coronary disease in 11% (22 of 197) of patients, and pre

149 Detection of occlusive coronary disease in heart transplant recipients with ele

150 properties in vitro, but its relationship to coronary disease in humans is unclear.

151 f this mouse model to the immunopathology of coronary disease in KD.

152 who underwent isolated CABG for multivessel coronary disease in New York.

153 Management of coronary disease in patients with advanced kidney diseas

154 dictors, after revascularization for complex coronary disease in patients.

155 This verified the significantly increased coronary disease in the non-synonymous dysfunctional var

156 sfunction as a precursor of clinically overt coronary disease in this specific risk group.

157 of age, with an emphasis on atherosclerotic coronary disease in those >/= 35 years of age.

158 raphy (MDCT) may be able to detect occlusive coronary disease in transplanted hearts.

159 type 2 diabetes mellitus and stable ischemic coronary disease in whom angina symptoms are controlled,

160 e) and ischaemic (ie, due to consequences of coronary disease) in developed countries, or rheumatic (

161 A total of 10,001 patients with documented coronary disease, including 4,654 with previous CABG, we

162 Both the aortic valve and the coronary disease influence the blood flow to the myocard

163 icardial Diseases, Congenital Heart Disease, Coronary Disease & Interventions, and CVD Prevention & H

164 icardial Diseases, Congenital Heart Disease, Coronary Disease & Interventions, and CVD Prevention & H

165 , Cardio-oncology, Congenital Heart Disease, Coronary Disease & Interventions, CVD Prevention & Healt

166 udes the sections: Congenital Heart Disease, Coronary Disease & Interventions, CVD Prevention & Healt

167 udes the sections: Congenital Heart Disease, Coronary Disease & Interventions, CVD Prevention & Healt

168 udes the sections: Congenital Heart Disease, Coronary Disease & Interventions, Genetics, Omics, & Tis

169 udes the sections: Congenital Heart Disease, Coronary Disease & Interventions, Genetics, Omics, & Tis

170 hies/Congenital & Genetics, Cardio-Oncology, Coronary Disease & Interventions, Hypertension, Imaging,

171 reserved for those patients with significant coronary disease irrespective of symptoms.

172 management of concurrent severe carotid and coronary disease is a subject of ongoing debate in the a

173 A GRS composed of 13 SNPs associated with coronary disease is an independent predictor of cardiova

174 Microvascular coronary disease is associated with an increased risk of

175 multivessel CAD, or LVD, if the severity of coronary disease is deemed to be complex (SYNTAX >22) du

176 rapy, with initiation recommended as soon as coronary disease is documented.

177 In cases in which coronary disease is less complex (SYNTAX </=22) and/or t

178 ch a risk reduction in patients with chronic coronary disease is limited.

179 The burden of coronary disease is lower in Mexican-American than in wh

180 ry intervention in patients with multivessel coronary disease is one of those rare situations in whic

181 s a risk of myocardial infarction unless his coronary disease is treated effectively before surgery.

182 t other risks and benefits of treatment, but coronary disease is typically not a major factor in the

183 ential to mitigate genetic predisposition to coronary disease is unclear.

184 (ejection fraction < or = 30%) and extensive coronary disease (Jeopardy Score > or = 8/12); those wit

185 ody mass index, persistent AF, hypertension, coronary disease, left atrial size, left ventricular eje

186 operated patients, and comorbidities such as coronary disease, left heart failure, and chronic obstru

187 hypertension and renal failure, but had less coronary disease, less previous cardiac surgery, and hig

188 If we are to eliminate coronary disease, lowering LDL should be the primary goa

189 tients without MI and with low likelihood of coronary disease (lowest Framingham risk category; n=103

190 with coronary bypass surgery for multivessel coronary disease mandate that surgeons reevaluate best p

191 can occur due to apical ballooning syndrome, coronary disease, medications, volume depletion, and val

192 with diabetes mellitus (DM) and multivessel coronary disease (MVD), coronary artery bypass grafting

193 d its use as a marker of risk for structural coronary disease, myocardial infarction, and cerebral va

194 291 patients presenting with acute or stable coronary disease needing stents >/=3.0 mm in diameter be

195 omen with AMI had lower rates of obstructive coronary disease (NSTEMI: P<0.001; STEMI: P=0.02), drive

196 pertrophic cardiomyopathy or atherosclerotic coronary disease, occurs primarily among male marathon p

197 t associated with risk markers, angiographic coronary disease (odds ratio, 1.03; 95% confidence inter

198 dies, the per-allele relative risks (RR) for coronary disease of factor V 1691A and of prothrombin 20

199 normalities, most frequently atherosclerotic coronary disease or cardiomyopathy.

200 ions and anatomy and PCI in less complicated coronary disease or deemed a high surgical risk.

201 men (mean age 60 years) without a history of coronary disease or diabetes at baseline from the Normat

202 pathy (OR, 1.24 [95% CI, 1.09-1.36]), and no coronary disease (OR, 1.20 [95% CI, 1.03-1.35]).

203 erences in the rates of infection, allograft coronary disease, or malignancy, but seven patients deve

204 eased mortality independent of hypertension, coronary disease, or other echocardiographic parameters.

205 s were observed regardless of age, extent of coronary disease, or PCI indication.

206 0 segments without angiographically apparent coronary disease (p = 0.004, adjusted p = 0.01).

207 ed: low ejection fraction, hypertension, and coronary disease (P<0.01).

208 In stable, predominantly asymptomatic coronary disease patients with a history of myocardial i

209 ASTEROID treated 507 coronary disease patients with rosuvastatin 40 mg/d for

210 ured by quantitative coronary angiography in coronary disease patients.

211 dent predictors of atherosclerotic burden in coronary disease patients.

212 medical versus invasive management of stable coronary disease, patients living in high-diagnostic-int

213 n patients matched for pretest likelihood of coronary disease (pCAD).

214 nary disease status (adjusted odds ratio for coronary disease per 1-SD increase in efflux capacity, 0

215 In patients with stable coronary disease, physiology (FFR) is a more important d

216 (median follow-up 2.5 years) with suspected coronary disease, plasma levels of 53 previously reporte

217 We review the genetics of CETP and coronary disease, preclinical data on CETP inhibition an

218 mic circumstances across a broad spectrum of coronary disease presentations, including acute coronary

219 d in the absence of a potentially lethal non-coronary disease process.

220 tions between the changes in CRP levels with coronary disease progression and MACE.

221 The effect of renin inhibition on coronary disease progression has not been investigated.

222 enic mechanisms associated with pathological coronary disease progression.

223 In patients with more extensive coronary disease, prompt CABG, in the absence of contrai

224 e rule-out protocol was used to evaluate for coronary disease, pulmonary embolism, aortic dissection,

225 osclerotic plaques of patients with unstable coronary disease raises the possibility that inhibition

226 ical trial of patients (n=1800) with complex coronary disease randomized to revascularization with pe

227 ed endpoint design, 532 patients with stable coronary disease receiving aspirin and/or clopidogrel (9

228 essel (25% vs 28%) and 3-vessel (23% vs 26%) coronary disease, regardless of ACS type.

229 ensity-matched using demographics, extent of coronary disease, regional wall motion, and quantitative

230 For a subset of patients with left main coronary disease, registry overcall was not linked to in

231 ch to managing coexisting severe carotid and coronary disease remains uncertain.

232 atients with any VHD had more heart failure, coronary disease, renal impairment, and persistent atria

233 oronary artery bypass graft) for multivessel coronary disease, repetitive transcranial magnetic stimu

234 of OMT remains low in patients with complex coronary disease requiring coronary intervention with pe

235 th recurrent polymorphic VT in patients with coronary disease responds to quinidine therapy when othe

236 tes has declined, and prevalences of several coronary disease risk factors have become comparable to

237 A total of 95% of patients had 2 or more coronary disease risk factors, and 25% had unstable symp

238 rebound to levels associated with increased coronary disease risk.

239 ed genes may also display genomic signals of coronary disease risk.

240 lial hypercholesterolaemia and patients with coronary disease secondary to raised levels of lipoprote

241 re inversely associated with patient age and coronary disease severity.

242 on the Evaluation of FFR-Guided Treatment of Coronary Disease), sharing a common design, were pooled

243 nt with atorvastatin in patients with stable coronary disease significantly reduces hospitalizations

244 In patients with more extensive coronary disease, similar to those enrolled in the coron

245 them for the treatment of acute and chronic coronary disease, specifically in the setting of acute c

246 x capacity was a strong inverse predictor of coronary disease status (adjusted odds ratio for coronar

247 ic; albeit, their prevalence correlated with coronary disease status (p = 0.017).

248 In patients with stable coronary disease, stenosis severity as assessed by FFR i

249 ed incidence of hypertension and, in men, of coronary disease, stroke, and heart failure.

250 Incident CVD, defined as coronary disease, stroke, or other atherosclerotic CVD d

251 Patients with diabetes have more extensive coronary disease than those without diabetes, resulting

252 that, among older patients with multivessel coronary disease that did not require emergency treatmen

253 omized trial involving patients with chronic coronary disease, the risk of cardiovascular events was

254 ries from 43 patients with various levels of coronary disease to assess the clinical relevance of the

255 onsistently demonstrated a family history of coronary disease to be predictive for future cardiovascu

256 ar benefits of treating patients with stable coronary disease to LDL-C levels substantially below 100

257 traditional indications such as diagnosis of coronary disease to novel applications such as in congen

258 randomly assigned 2287 patients with stable coronary disease to PCI plus optimal medical therapy or

259 ind trial, we assigned patients with chronic coronary disease to receive 0.5 mg of colchicine once da

260 itus and angiographically documented, stable coronary disease to strategies of (1) prompt revasculari

261 are frequent among patients with symptomatic coronary disease treated by percutaneous coronary interv

262 Patients with multivessel coronary disease treated with coronary artery bypass gra

263 Relevance: Among patients with angiographic coronary disease treated with statins, addition of evolo

264 Among patients with established coronary disease, treating to an LDL-cholesterol substan

265 For patients with coronary disease, treatment with an ACAT inhibitor did n

266 n efficient surrogate for clinical events in coronary disease trials?

267 consecutive patients with known or suspected coronary disease undergoing exercise MPGS between 1997 a

268 Methods: Twenty-eight patients with stable coronary disease underwent a 30-min PET acquisition 1 h

269 raction (mean 64 +/- 5%) and no angiographic coronary disease underwent CMR (cine and delayed post-co

270 f 86 patients with angina but no obstructive coronary disease underwent coronary pressure and flow me

271 2000 and 2007, 8,837 patients with new onset coronary disease underwent initial CABG, and 14,516 unde

272 A total of 1188 patients with coronary disease underwent intravascular ultrasonography

273 5), in which 1455 patients with angiographic coronary disease underwent serial intravascular ultrason

274 have separate and opposite associations with coronary disease, using waist circumference alone may pr

275 rent effective cardiovascular treatments for coronary disease, vascular atherosclerosis, ectasia and

276 s >/=80 years of age frequently have complex coronary disease warranting DES but have a higher risk o

277 ical angina, and the pre-test probability of coronary disease was 49%.

278 Adults whose first clinical presentation of coronary disease was either acute myocardial infarction

279 The Framingham Risk Score for patients with coronary disease was used to summarize clinical risk.

280 mized, controlled trials, relative risks for coronary disease were 0.97 (CI, 0.69 to 1.36) for alpha-

281 In observational studies, relative risks for coronary disease were 1.02 (95% CI, 0.97 to 1.07) for sa

282 or echocardiographic evidence of valvular or coronary disease were age and gender matched to a refere

283 ar, p<0.0001), and the main risk factors for coronary disease were also risk factors for bleeding.

284 phic ventricular tachycardia associated with coronary disease were analyzed for cardiovascular-specif

285 Symptomatic patients without known coronary disease were enrolled into 2 strata based on wh

286 Women with confirmed coronary disease were less likely to be revascularized t

287 nterventions: Participants with angiographic coronary disease were randomized to receive monthly evol

288 Patients (n=10,001) with stable coronary disease were randomized to treatment with atorv

289 Patients with multivessel coronary disease were recruited into a randomized trial

290 isting mitral regurgitation, and preexisting coronary disease were significant predictors of primary

291 he long-term outcome of patients with stable coronary disease when used as initial therapy.

292 revious myocardial infarction or multivessel coronary disease who additionally had either type 2 diab

293 n alternative option in patients with severe coronary disease who are considered 'high risk' for CEA.

294 th suspected ischemic heart disease or known coronary disease who had clinical indications for cardia

295 uld provide another option for patients with coronary disease who require further reduction in LDL (l

296 hether rimonabant is useful in management of coronary disease will require additional imaging and out

297 , multicenter study of patients with FMR and coronary disease with core laboratory analysis.

298 ular events of treating patients with stable coronary disease with low-density lipoprotein cholestero

299 e re-appraise a large-scale meta-analysis of coronary disease with RE2C to search for small-effect ge

300 wed no significant overall associations with coronary disease, yielding per-allele RRs of 0.97 (0.91-